An observational study in Magnetic Resonance Imaging, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by University Health Network, Toronto · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Liver Neoplasms with a site in Canada — 13 open to participants now, 22 under way, 3 of them phase 3. Liver Neoplasms · Canada.
Among the 70 studies in Liver Neoplasms with a site in Canada, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2018, is one of 13 observational ones, reaches primary completion later than 10 of the 21 other live ones, and was the 45th registered.
1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.
Browse Liver Neoplasms studies →13 of the 70 studies in Liver Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18–70
Centre hospitalier de l'Université de Montréal (CHUM) · Sites in Canada
Ages 18+
Maastricht University · Sites in Canada, United States, Australia and 6 more countries
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Maastricht University Medical Center · Sites in Canada, United States, Australia and 10 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 19 · Phase 3 18 · Phase 4 3
First in 1992; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 200 across 344 observational studies indexed under Liver Neoplasms.
Median enrollment 116 across the 56 interventional studies, 328 across the 13 observational. Of the 42 that completed or were terminated, 19 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 70 have an industry lead sponsor. The 10 most frequent:
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
University Health Network, Toronto has 7 studies filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
9 of the studies in Liver Neoplasms with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02869217University Health Network, TorontoStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | 2026-11 |
| NCT05953337ABK BiomedicalRadioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | 2027-02 |
| NCT03582189University Health Network, TorontoMR Guidance for Liver and Pancreas | 2027-02 |
| NCT04008797Eisai Inc.A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | 2027-03-31 |
| NCT05185505The Methodist Hospital Research InstituteAtezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | 2027-04-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 70 studies in Liver Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single centre, single arm, prospective feasibility study that aims to see whether magnetic resonance imaging (MRI) as a source of image guidance before each radiation treatment fraction is feasible, and also if it may provide information that could potentially be used during the treatment to improve the radiation treatment plan.
Patients will have 5 MRIs with each of their RT sessions. If patients' RT treatment will consist of more than 5 fractions, only 5 MRIs will be done with any 5 RT fractions. Patients will be completing a short questionnaire at the end of each MRI. A patient questionnaire will also be completed at the end of the study to assess for patient satisfaction.
There will be 30 evaluable patients enrolled to the study.
Patients diagnosed with locally advanced pancreatic cancer or hepatocellular carcinoma being considered for treatment with chemoradiation, long course RT, or SBRT with curative intent or palliative intent, planned for 5 or more RT fractions
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- for MRI: ferromagnetic prosthesis, pacemaker / implanted defibrillator, claustrophobia
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 10 patients with pancreatic cancer will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
Other: MRI
Approximately 10 patients with liver mets will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
Other: MRI
Approximately 10 patients with HCC will be enrolled to the study with the primary aim of determining the feasibility of using off-line MRI-guidance during the course of radiation treatment
Other: MRI
Patients who consent to this study will have an abdominal MRI prior to or immediately after each fraction of radiation treatment in the case of those patients that are undergoing SBRT or those receiving palliative treatment. On patients receiving definitive chemoradiation, an abdominal MRI will be performed prior to or immediately after radiation treatment once per week during the any five weeks of treatment
Patient Satisfaction Survey
To evaluate patient satisfaction with the MR guidance process, a modified version of a questionnaire previously used at our institution will be performed at the end of the study
Time frame: At study completion (day5 or week 5, depending on type of treatment)
MRI-Anxiety Questionnaire
This instrument will be used to evaluate patient related anxiety after each MR
Time frame: Prior to or before MR session 1 (day 1 or week 1, depending on type of treatment)
MRI-Anxiety Questionnaire
This instrument will be used to evaluate patient related anxiety after each MR
Time frame: Prior to or before MR session 2 (day 2 or week 2, depending on type of treatment)
MRI-Anxiety Questionnaire
This instrument will be used to evaluate patient related anxiety after each MR
Time frame: Prior to or before MR session 3 (day 3 or week 3, depending on type of treatment)
MRI-Anxiety Questionnaire
This instrument will be used to evaluate patient related anxiety after each MR
Time frame: Prior to or before MR session 4 (day 4 or week 4, depending on type of treatment)
MRI-Anxiety Questionnaire
his instrument will be used to evaluate patient related anxiety after each MR
Time frame: Prior to or before MR session 5 (day 5 or week 5, depending on type of treatment)
Started Jul 2018 (actual). Primary completion is estimated for Feb 2027, 103 months after the start.
Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 103 months is close to that.
Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →